Identification of a sub-micromolar, non-peptide inhibitor of β-secretase with low neural cytotoxicity through in silico screening by Xu, W. et al.
 
 NOTICE: this is the author’s version of a work that was accepted for 
publication in Bioorganic & Medicinal Chemistry Letters. Changes 
resulting from the publishing process, such as peer review, editing, 
corrections, structural formatting, and other quality control 
mechanisms may not be reflected in this document. Changes may 
have been made to this work since it was submitted for publication. 
A definitive version was subsequently published in Bioorganic & 




Identification of a sub-micromolar，Nonpeptide Inhibitor of β-secretase 1 
with low neural cytotoxicity through In-silico Screening 2 
 3 
Weijun Xua, Gang Chenb, Weiliang Zhuc*, Zhili Zuod* 4 
aSchool of Chemical and Life Sciences, Singapore Polytechnic, Singapore 139651 5 
bCentre for Biomedical and Life Sciences, Singapore Polytechnic, Singapore 139651 6 
cDrug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of 7 
Sciences, Shanghai 201203, China 8 
dSchool of Biomedical Sciences, Curtin University, Perth WA 6485, Australia 9 
 10 
*: Corresponding authors. 11 
Please address correspondence and requests for reprints to: 12 
Dr Zhili Zuo 13 
School of Biomedical Sciences, Curtin University, GPO Box U1987 Perth, Western Australia 14 
6845, Australia. 15 
Email: z.zuo@curtin.edu.au 16 
Dr Weiliang Zhu 17 













Nowadays identification of novel non-peptide β-secretase (BACE-1, hereinafter) inhibitors with 2 
low cytotoxicity and good blood-brain barrier (BBB) property holds common interest of drug 3 
discovery for Alzheimer’s disease. 20 SPECS compounds were tested in BACE-1 FRET assays 4 
and methylthiazoletetrazolium (MTT) cytotoxicity experiment. Two compounds: 2 and 15 5 
demonstrated IC50 values of 0.53 and 9.4 μM. In addition, 2 showed least toxic effect to the 6 
neuroblastoma cells. The results from both in silico and in vitro studies provided new 7 
pharmacophoric entities for chemical synthesis and optimization on the current discovered 8 


















Alzheimer’s disease (AD) is a chronic neurodegenerative disorder of the central nervous 2 
system, resulting in severe cognitive deficits along with psychiatric complications. More than 37 3 
million individuals suffer from this condition and the number is expected to continue growing 4 
dramatically1, 2. Five drugs that are currently on the market – the cholinesterase inhibitors 5 
donepezil, rivastigmine, galantamine, and tacrine, the N-methyl-D-aspartate (NMDA) receptor 6 
modulator memantine approved for the treatment of symptoms of AD.3 However, they are unable 7 
to halt or reverse the disease progression. The major pathological hallmark of AD is the 8 
deposition and aggregation of amyloid β-peptide (Aβ) in the brain tissues and hence leads to 9 
intracellular formation of neurofibrillary tangles. This small peptide consists of 39-43 residues 10 
that are endo-proteolytically derived from a transmembrane amyloid precursor glycoprotein 11 
(APP)4. Aβ production involves the sequential actions of two proteases, the BACE-1 and γ-12 
secretase5.  Inhibition of these enzymes by small molecule interference is a promising strategy to 13 
prioritize pharmaceutical candidates and such approach was highly encouraged by the discovery 14 
in 2001 that no Aβ were generated in BACE-1 knockout mice which were devoid of BACE-1 15 
activity and displayed a normal phonotype6. In the past, the major effort in designing BACE-1 16 
inhibitors was the production of transition state isosteres such as hydroxyethylamines, reduced 17 
amides, statine-based peptidomimetic inhibitors countering the catalytic aspartyl groups. 18 
Although large number of potent peptidomimetic inhibitors can be generated, their relatively 19 
large size and number of hydrogen bond donors and acceptors make it challenging to achieve 20 
high oral bioavailability7, 8. Therefore, identification of novel small molecule non-peptide 21 
inhibitors with balanced ADMET properties will make the chemicals more favorable for further 22 
development into leads and drugs. Some non-peptide compounds were identified as inhibitors of 23 
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BACE-1. Astex researchers highlighted their work in discovering aminopyridine and cyclic 1 
amidine classes as BACE-1 inhibitors9. Barrow et al reported the identification of 2 
spiropiperidine inhibitor template for BACE-110. More recently, researchers from Weyth 3 
described their identification of aminohydantoins as potent BACE-1 inhibitors11. The most 4 
prominent inhibitor was from GSK group which generated GSK188909 as the first orally 5 
available BACE-1 inhibitor showing its therapeutic effect in an animal model12. More 6 
information on non-peptide inhibitors of BACE-1 was reviewed by Huang et al13. Despite the 7 
painstaking effort put in discovering drug candidates for AD, no truly disease modifying agents 8 
are yet available14. Hence, investigations on new drug discovery and development for AD draw a 9 
great deal of interest to the medicinal chemists.  10 
Herein, we report the discovery of two novel BACE-1 small organic inhibitors via a receptor-11 
based virtual screening followed by compound drug-likeness analysis, cytotoxicity prediction, 12 
and bioassays. Scheme 1 shows the overall approach adopted in this study. The preparation of 13 
protein structure was done according to our previously reported protocol15. The SPECS chemical 14 
library (~280,000 compounds) was screened using GOLD 3.0.1 with default parameters. The 15 
active site radius is 10Ǻ from atom 1869 (OG1) of amino acid Thr232 which was one of the key 16 
amino acid residues in BACE-1. The GoldScore fitness function was applied and top 5000 17 
molecules with the highest scores from initial virtual screening were then re-submitted for 18 
multiple docking of 10 conformations for each ligand. Finally, the top 200 hits were kept for 19 
further selection. To select which of the in silico compounds would be purchased and tested in 20 
vitro, several factors were taken account in this step and these included: 1) Information on 21 
molecular weight, predicted LogP, LogS and toxicity values of the compounds, toxicity 22 
prediction by Pallas (Compudrug Pty Ltd) software; 2) Our knowledge in the molecular 23 
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interactions between BACE-1 and its substrate, together with the predicted putative H-bonds 1 
formed by the hits and active site residues of BACE-1, potential hydrophobic interaction and 2 
aromatic-aromatic interactions. Based on the factors stated above, the consensus judgment from 3 
both of the selection criteria led us to purchase 20 compounds for enzymatic assays. These 4 
compounds mostly have molecular weights < 550 Da, LogP < 8, hydrogen bond donor < 3, and 5 
hydrogen bond acceptor < 7. The features were considered as favourable physicochemical 6 
properties of CNS drugs as highlighted in Pardridge’s review16. Finally twenty SPECS 7 
compounds were purchased and tested for their inhibitiory activities against BACE-1 in FRET 8 
assays. BACE-1 inhibition assays were carried out using Fluorescense Resonance Energy 9 
Transfer (FRET) assay kits according to the protocol described previously[15]. 6 compounds 10 
exhibited over 50% inhibition of BACE-1 activity at 100µM. Among them, 2 and 15 had IC50 11 
values of 0.53µM (Figure 1) and 9.4µM respectively. Table 1 shows the structures of the 12 
inhibitors and their enzyme assay results. To elucidate the possible interactions between the 13 
inhibitors and their active binding site, the docked conformations of 2 and 15 were superimposed 14 
in the binding site and the docked poses enabled us to understand the main protein-inhibitor 15 
interactions. The top scored conformations were selected and showed from all conformations 16 
generated by GOLD. As shown in Figure 2, 2 and 15 fell into two different interaction patterns 17 
with BACE-1. Compound 15 was docked into only half of the BACE-1 active pocket (S1’, S1, 18 
S2 and S3). Figure 3 depicts the detailed binding modes of the inhibitors in BACE-1. The bulky 19 
aromatic groups in 15 made it mainly interact via hydrophobic contacts with the surrounding 20 
active residues such as Thr 231, Thr 232, and Tyr71 (Figure 3(b)). In contrast, compound 2 21 
spanned the binding with the extension to the prime side of the active site, as seen by the 22 
occupancy of the S4’ sub-site (Figure 3(a)). In particular (refer to Figure 4), the ethoxyphenyl 23 
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occupies the intermediate space between S3 and S4, forming Van der Waals interaction with Leu 1 
30 and Ile 110. The phenyl pyrozol group is more exposed to the solvent but a π-cation 2 
interaction could be present between Arg 235 and this group and further stabilizing the binding 3 
of 2 entropically. Interestingly, unlike other reported inhibitors which are capable of forming 4 
multiple hydrogen bonds with the two aspartic acid residues in BACE-1, 2 does not contain a 5 
moiety to form hydrogen bonds with either of the aspartic acid residues (Asp 32 or Asp 228) in 6 
the S1 catalytic hole. Instead, a benzene ring occupies the S1 region. The aromatic-aromatic 7 
interaction with Tyr 71 and Phe 108 could be the reason for an aromatic group to be localised at 8 
the S1 of BACE-1 by GOLD. In addition, due to the hydrophobic nature in the S1-S3 region, it is 9 
reasonable that a large hydrophobic or aromatic group should be well tolerated. The overall 10 
comparison in the binding modes of compound 2 and 15 derived from docking were hence in 11 
good agreement with the difference in their inhibitory potencies from enzyme assays.  12 
To validate the toxicity prediction from Pallas, MTT assays17 were conducted on the 13 
neuroblastoma cell line SH-SY5Y. MTT reacted with the mitochondrial succinic dehydrogenase 14 
in the living cells to produce a dark-purple formazan and the reaction was indicative of the 15 
presence of viable cells17. Neuroblastoma cell lines, SH-SY5Y, were purchased from ATCC 16 
through local vendor. The base medium mixture was created using F12 medium and ATCC-17 
formulated Eagles’s minimum Essential medium with a ratio of 1:1. The complete medium was 18 
formed by adding FBS, fetal bovine serum into the base medium with the final concentration of 19 
10%. Cells were cultured in T25 flasks containing 7ml of complete medium. The flask was 20 
incubated for 5 to 7 days at 37̊C in 5% CO 2 incubator. The SH-SY5Y cells were sub-cultured 21 
and fed with fresh medium every 5 to 7 days. Briefly, the test compounds were serially diluted 22 
by complete medium to achieve final concentrations ranging from 12.5µM to 1.56µM in the 96-23 
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well plate. 100 µl of test compound was added into the neuroblastoma cells pre-seeded at the 1 
concentration of 3 x 105cells/ml and incubated for 4 days. Total DMSO concentration in the well 2 
is less than 2%. Next, 100 µl of MTT solution was introduced to each well (final MTT 3 
concentration = 0.5mg/ml) and incubated for 4 h at 37oC + 5% CO2. Finally, 100 µl of detergent 4 
(sodium dodecyl sulfate + isobutanol + 36.5% hydrochloric acid) was added into each well and 5 
the absorbance values of 570nm and 630nm (reference) was taken after overnight incubation. 6 
The culture medium was used as control in the MTT experiment. The cell viability percentage 7 
was calculated using the formula (A570-A630)sample / (A570-A630) control x 100%. 8 
Compound 2 was tolerable by the cells at a concentration of up to 25µM whereas compound 9 
15 exhibited a 50% reduction in cell viability at 12.5µM. Hence, compound 2 showed a 50-fold 10 
selectivity in inhibitory potency over toxic effect. Meanwhile, 2 has a molecular weight of 489, 11 
predicted LogP of 4.93, LogS of -8.4, 6 hydrogen bond acceptors and 1 hydrogen bond donor. 12 
These features make it nearly fit the criteria for being CNS drugs especially for the BBB 13 
permeation16. The overall “portfolio” of 2 suggested it is an attractive hit and worth taking 14 
downstream steps to make it into lead compounds against AD.  15 
   Albeit 2 showed BACE-1 inhibition at sub-micromolar, there is still no enough information 16 
whether it can reduce the Aβ from the cells. Future work on the measurement of the secreted 17 
amount of Aβ from the current cell line will help us understand more on the medicinal potential 18 
of compound 2.  19 
   In conclusion, an in-silico virtual screening of commercial database SPECS together with 20 
enzyme assays and cell-based toxicity testings resulted in the identification of two novel non-21 
peptide inhibitors of human BACE-1. 2 emerged as a sub-micromolar inhibitor (IC50 0.53 µM) 22 
with low cytotoxicity. Docking of compound 2 in the BACE-1 active site revealed that a central 23 
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hydrophobic benzene ring occupied the aspartic acid catalytic holes and also suggested the 1 
putative binding and interactions with other sub-sites. MTT assays indicated compound 2 was 2 
well tolerated by the brain cell line SH-SY5Y. Therefore, we believe that future effort in 3 
optimizing present sub-micromolar hit into more potent nanomolar leads based on the molecular 4 




We gratefully acknowledge financial support from student Toteboard project funding 11-27801-9 
45-2703, Singapore Polytechnic, 863 program of China (2006AA02Z336) and international 10 
collaboration program of China (2007DFB30370). We thank Libin Guan, Xiaotong Huang, and 11 
Donglin Ying for the help in bioassay and cell culture work. We also thank Dr Oi Wah Liew and 12 
Ms Jenny Chong for helping us our bioassays on the TECAN fluorometer. We take the 13 
opportunity to thank Compudrug for allowing us using the Pallas demo software for predictions 14 









Scheme 1. Flowchart of virtual screening and bioassays for discovering BACE-1 inhibitors. 2 
 3 
Table 1. BACE-1 inhibition results of compound 2 and 15. 

















[a] Initial screen were carried out in duplicate and results were presented as the average value. [b] IC50 was 
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Figure 2. Superimposed binding of 2 and 15 derived from docking by GOLD. Compound 2 is colored by yellow 7 
and Compound 15 is indicated using green. Protein surface is colored white. Surfaces of catalytic aspartic acids 32 8 
and 228 are colored in red. Two residues, Thr 72 and Gln 73, were deleted for a whole view of active site. Sub-sites 9 
of BACE-1 are labeled in black. The picture was generated by Pymol. (DeLano, W.L. The PyMOL Molecular 10 




Figure 3. Cartoon representation of BACE-1 active site. Key residues are shown in stick and colored by atom type. 2 
a) Molecular docking pose of compound 2 b) Molecular docking pose of compound 15. The binding mode was 3 
derived from GOLD and the picture was generated by Pymol software. 4 
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